Araştırma Makalesi

Pupillary response changes in Graves' disease

Cilt: 48 Sayı: 2 2 Temmuz 2023
PDF İndir
TR EN

Pupillary response changes in Graves' disease

Abstract

Purpose: The aim of this study was to investigate pupillary contraction and dilatation response changes in Graves' disease. Materials and Methods: The patient group consisted of 55 euthyroid Graves patients and the control group consisted of 55 healthy individuals. Data from the right eyes of all participants were used. Static (scotopic, mesopic, photopic) and dynamic pupillometry measurements were performed with automatic pupillometry. The mean pupil dilatation speed was calculated according to dynamic measurements. Static measurements, dynamic measurements and the mean pupil dilatation speed data were compared between the patient and control groups. Results: There was no statistically significant difference between two groups in all static and dynamic values and the mean pupil dilatation speed. The mean scotopic pupil diameter was 5.41±0.776 mm in Graves’ group and 5.55±0.747 mm in the control group. The mean mesopic pupil diameter was 4.39±0.721 in Graves’ group and 4.17±0.640 mm in the control group. The mean photopic pupil diameter was 3.45 ±0,549 mm in Graves’ group and 3.29±0.679 mm in the control group. The mean dynamic pupil diameter 0th second was 3, 54±0.541 mm in Graves’ group and 3.48±0.708 mm in the control group. The mean speed of pupil dilatation at 18th second was 0.116±0.031 mm/sec in Graves’ group and 0.128±0.040 mm/sec in the control group. Age was found to be an independent factor on pupillary parameters. Conclusion: The pupillary parameters of patients with euthyroid hormone levels were not affected. While pupillary responses appeared not to be affected in the case of euthyroidism, more studies including patients with hypothyroidism and hyperthyroidism are needed.

Keywords

autonomic nervous system , pupil dilatation speed , pupillometry , thyroid function tests , Graves

Kaynakça

  1. Kahaly GJ. Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020;105:3704-20.
  2. Ehlers M, Schott M, Allelein S. Graves' disease in clinical perspective. Front Biosci (Landmark Ed). 2019;24:35-47.
  3. Weiler DL. Thyroid eye disease: a review. Clin Exp Optom. 2017;100:20-25.
  4. Eslami F, Borzouei S, Khanlarzadeh E, Seif S. Prevalence of increased intraocular pressure in patients with graves' ophthalmopathy and association with ophthalmic signs and symptoms in the north-west of Iran. Clin Ophthalmol. 2019;13:1353-59.
  5. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.
  6. Hamada N, Okamoto Y, Yoshida H, Tsumura K, Nakamura Y, Noh JY. Sympathetic overactivity in the development of eyelid retraction in a patient with euthyroid graves' disease evaluated by accommodation. Endocr J. 2000;47:623-8.
  7. Gon Y, Sakaguchi M, Oyama N, Mochizuki H. Diagnostic utility of contrast-enhanced 3D T1-weighted imaging in acute cerebral infarction associated with graves disease. J Stroke Cerebrovasc Dis. 2017;26:e38-40.
  8. Rodríguez-Alonso X, Gutiérrez-Jorrín S, Bonnin-Arias C, Rubio-Corgo S, Arregui-Olaizola C, Quezada-Sánchez J, et al. Mesopic pupillary reflex in patients treated with fluoxetine. Actas Esp Psiquiatr. 2020;48:47-53.
  9. Serbest Ceylanoglu K, Sen EM, Sekeroglu MA. Static and dynamic pupillary features in graves' ophthalmopathy. Clin Exp Optom. 2022:1-5.
  10. 10.Eckstein A, Dekowski D, Führer-Sakel D, Berchner-Pfannschmidt U, Esser J. Graves' ophthalmopathy. Ophthalmologe. 2016;113:349-64; quiz 465-6.

Kaynak Göster

MLA
Yıldırım Biçer, Gamze, vd. “Pupillary response changes in Graves’ disease”. Cukurova Medical Journal, c. 48, sy 2, Temmuz 2023, ss. 361-8, doi:10.17826/cumj.1229467.